Better Health,
Brighter Future
Newsroom
Careers
Investors
United States
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Takeda in the U.S.
Worldwide Offices
Executive Leadership
Corporate Philosophy
Contact Us
What We Do
Our Business
Takeda continues its transformation into an agile and innovative global pharmaceutical leader, serving the needs of patients and physicians worldwide.
Learn more
Patient Services
U.S. Product List
Research & Development
Our Pipeline
Therapeutic Areas
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
In Their Shoes
The Key Elements at the Heart of Our Innovation
Partnerships as Catalysts for Innovation
Caring
Medicine for the World
Heritage
Keys to Aging Gracefully
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
Learn more
Commitment to Community
Our Environment
Culture of Compliance
Federal
CPSIA
State
Open Payments and Transparency Reporting
Diversity and Inclusion
Independent Medical Education Grants
Takeda Pricing Philosophy
Lobbying & Political Contributions
Patient Assistance
ADHD Medicines Misuse
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
NATPARA Updates
COVID-19 Updates
News Releases
Enter
All
Last 12 months
2017
2016
2015
2014
2013
2012
2009
2008
2007
2005
2004
2003
2002
2000
December 2019
December 9, 2019
12/9/2019
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
November 2019
November 6, 2019
11/6/2019
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
October 2019
October 28, 2019
10/28/2019
First-Ever U.S. Pivotal Phase 3 Clinical Study in Eosinophilic Esophagitis (EoE) Completes
October 10, 2019
10/10/2019
Working Mother Names Takeda as One of the 2019 100 Best Companies
September 2019
September 25, 2019
9/25/2019
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
September 24, 2019
9/24/2019
Takeda Announces NATPARA® Special Use Program in the US
September 13, 2019
9/13/2019
Message about the US NATPARA Recall
September 5, 2019
9/5/2019
Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate
1
2
3
4
5
TOP
